HER2 Biomarkers News and reporting on HER2 biomarkers. Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion Premium The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients. Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor. Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment. Hummingbird Biosciences, Tempus Partner to ID Cancer Patients for Anti-HER3 Treatment Trial The collaboration, through which Hummingbird will have access to Tempus' TIME Trial Network, is focused on advancing the HER3-targeted agent, HMBD-001. Spanish Startup Aims to Develop Novel Genomic Tests to Guide Breast Cancer Treatment Premium Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision. Aug 17, 2020 Thermo Fisher Scientific, Hengrui Therapeutics Ink CDx Deal for Pyrotinib in HER2-Mutated NSCLC Jun 12, 2020 New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes Premium Feb 13, 2020 Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel Oct 31, 2019 HER2 Amplification Confers Drug Sensitivity Across Tumor Types in New Study Premium Oct 18, 2019 Cervical Cancer Exomes Point to Potentially Targetable HER, PIK3CA Pathway Changes Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Jun 13, 2019 ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer Premium Apr 3, 2019 Project GENIE Used to Explore Impact of Rare Cancer Mutations on Treatment Response Premium Mar 4, 2019 Colon Cancer Patients Could Benefit From HER2 EGFR Non-Response Findings, Investigators Say Premium Dec 10, 2018 Metastatic ER+ Breast Cancers Acquire HER2 Mutations to Become Treatment Resistant Dec 5, 2018 Genentech Data Shows Breast Cancer Patient Subgroups May Benefit from Its Drugs Premium Sep 5, 2018 Study IDs Triple-Negative Breast Cancer Patients Who Respond to HER2-Targeted Therapy Premium Jul 17, 2018 Strata Oncology to Aid Puma Biotech in Recruiting for Neratinib HER2 Basket Study Feb 1, 2018 Publication Highlights Key Questions as Basket Studies Proliferate Premium Apr 12, 2017 After Korean Clinical Approval for Breast Cancer Prognostic, Gencurix Looks to Asian, US Markets Premium Apr 3, 2017 HER2 Mutant Basket Trial Confirms Drug Response Depends on Mutation, Cancer Type Mar 3, 2017 BioNTech Gathering Data Supporting MammaTyper Over Manual, Digital IHC for Breast Cancer Subtyping Premium Nov 14, 2016 Oncologists, Pathologists Issue HER2 Testing Guidance for Gastroesophageal Cancer Patients Aug 24, 2016 Harvard Breast Cancer Study of HER2 Expression Identifies New Potential Treatment Options Premium Jul 13, 2016 HER2-Positive Breast Cancer Heterogeneity Revealed in Genomic, Transcriptomic Patterns Load More Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.